Sensei Biotherapeutics is pioneering the development of precision cancer therapeutics that target a novel and untapped tumor-specific antigen called ASPH, or aspartate β-hydroxylase. ASPH is expressed in more than 20 cancer types, both solid and hematologic tumors, and correlates with poor patient survival. Our therapeutics are immunologically optimized to effectively promote robust and multi-functional, target-specific immune response, and are being developed with proprietary companion diagnostics to enable precision medicine through highly-specified patient selection.
